Clinical trials: Avelumab
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasms
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
The study is primarily designed to assess the safety and tolerability of escalating oral doses of Debio 1143 and preliminary anti-tumour activity when combined with the standard dose of avelumab in participants with advanced…
- Trial name
- NCT03270176
- Testing
- Debio 1143, Avelumab
- Where
- 9 sites in Canada, Poland and 1 more
- Volunteers
- 54 people
- Sponsor
- Debiopharm International SA
Renal Cell Cancer
Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
This study is a phase 2, multicenter, interventional for cohort 1 \& 2, non-interventional for cohort 3, open-label trial of cabozantinib, with ORR as the primary efficacy endpoint.
- Trial name
- NCT04714697
- Testing
- Cabometyx
- Where
- South Korea
- Volunteers
- 201 people
- Sponsor
- Asan Medical Center
Arthritis, Cancer
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin.
- Conditions
- Arthritis, Cancer, Cardiac Disease, Endocrine System Diseases
- Trial name
- CHIMeRA (NCT03492242)
- Testing
- Immune checkpoint inhibitor
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Solid Tumors, Soft-tissue Sarcoma
A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Assessment of the efficacy and safety of JX-594 and metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma and advanced breast cancer, once the Maximum Tolerated Dose have been determined (phase I trial).
- Conditions
- Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
- Trial name
- METROmaJX (NCT02630368)
- Testing
- Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide
- Where
- France
- Volunteers
- 197 people
- Sponsor
- Institut Bergonié
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer
Recurrent Glioblastoma (WHO-Grade IV Glioma)
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior…
- Trial name
- GliAvAx (NCT03291314)
- Testing
- Axitinib, Avelumab
- Where
- Belgium
- Volunteers
- 52 people
- Sponsor
- Universitair Ziekenhuis Brussel
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Soft Tissue Sarcoma Adult
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
- Trial name
- NCT03056599
- Testing
- Multiple drug microinjection, CIVO device
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Presage Biosciences
Meningioma, Meningioma, Adult
Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Meningioma is the most common central nervous system (CNS) tumor and accounts for approximately 30% of all CNS tumors. For meningioma recurring after surgery and radiation therapy, there is no effective medical therapy.
- Trial name
- NCT03267836
- Testing
- Avelumab, Proton Therapy, Surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Washington University School of Medicine
Gastric Adenocarcinoma, Oesophageal Adenocarcinoma
Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer
A single centre phase II trial of peri-operative chemo-immunotherapy in operable gastro-oesophageal adenocarcinoma (GOA). This trial is designed to evaluate the safety and efficacy of administering Avelumab, an anti-PD-L1…
- Trial name
- ICONIC (NCT03399071)
- Testing
- FLOT-A
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Hodgkin Lymphoma
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with with CD20-positive NHL who have progressed on or after rituximab therapy.
- Trial name
- NCT03169790
- Testing
- avelumab, bevacizumab, capecitabine
- Sponsor
- ImmunityBio, Inc.
Thymoma, Thymic Carcinoma
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Background: Thymoma and thymic carcinoma are cancers originating in the thymus gland. Platinum-based chemotherapy is standard treatment for them.
- Trial name
- NCT03076554
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of…
- Trial name
- NCT02952586
- Testing
- Avelumab, Chemoradiation
- Where
- 316 sites in United States, Australia and 20 more
- Volunteers
- 697 people
- Sponsor
- Pfizer
Metastatic Urothelial Cell Cancer
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
This is a single arm, open-label phase Ib study of combining eribulin mesylate with avelumab. The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.
- Trial name
- NCT03502681
- Testing
- Eribulin Mesylate, Avelumab
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Monika Joshi, MD
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refractory to or has relapsed following initial treatment.
- Trial name
- AVAIL-T (NCT03046953)
- Testing
- Avelumab
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University of Birmingham
Locally Advanced or Metastatic Urothelial Carcinoma
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
- Trial name
- NCT05327530
- Testing
- Avelumab, Sacituzumab Govitecan (SG), M6223
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 256 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8
Adjuvant Avelumab in Merkel Cell Cancer
This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy.
- Conditions
- Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
- Trial name
- ADAM (NCT03271372)
- Testing
- Avelumab, Peripheral Blood Collection
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- University of Washington
Pancreatic Cancer Resectable
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
This is a randomized phase II trial that will examine the ability of Avelumab to improve the clinical activity of a pre-operative regimen of gemcitabine, nab-paclitaxel and hydroxychloroquine in subjects with potentially…
- Trial name
- 17-134 (NCT03344172)
- Testing
- Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab, Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Bahary, MD
Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of Avelumab to the perioperative chemotherapy in…
- Trial name
- MONEO (NCT03979131)
- Testing
- Avelumab addition to perioperative chemotherapy in GC and GEJC
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology